Replies to post #151905 on Biotech Values

[iwfal]

MNTA -

Is there a more promising biotech company with an enterprise value of $275M or less

Arguably many. Especially since Momenta's valuation has sooo many uncertainty factors in it and it is sooo far away in time:

a) Will the FDA actually allow substitutible FOBs? - Both in theory and in practice?

b) How long will it take to get it approved after submission? 8 years?

c) Will the drug still be viable after 8 years or will the market have been eroded due to non-sub generics. Or improved competitive products?

d) Will patents be enforceable? Or do trade secrets have to suffice - in which case competition will probably happen quicker?

e) Will Momenta ever move forward with any speed on the improved biologics? And if they do, what is the risk that the improvement is not enough?

[alertmeipp]

Dew, mind to update your sum of parts valuation post? TIA

[zipjet]

MNTA—Is there a more promising biotech company ...

I would say it has been the most promising biotech of this millennia with no fulfillment.

ij